Alnylam PharmaceuticalsALNY

Jefferies analysts raised their target price for the stock to $260 but kept a hold rating, which means they suggest keeping what you own rather than buying more. This new target is close to where the stock currently trades and sits well below the average analyst target of about $347. While other firms are more optimistic about the company's growth in heart disease treatments, this move suggests Jefferies is waiting for more evidence before fully backing the stock's recent climb.

Source: Jefferies

Alnylam presented new data at a major cardiology conference regarding its drug Amvuttra. The findings show the treatment effectively silences the specific protein that causes a dangerous buildup in the heart, known as ATTR-CM, across a wide range of patient groups and disease stages.

This is important because Amvuttra is the engine of the company's future growth. Proving it works consistently across different treatment settings helps Alnylam compete with Pfizer's existing drug in this market. While these results reinforce what we already knew from earlier trials, they provide the extra clinical evidence doctors look for when deciding which medicine to prescribe.

Source: Business Wire

Alnylam is scheduled to present new data for its heart disease and high blood pressure programs at the European Society of Cardiology Congress starting August 28. These presentations will include real-world evidence for its core treatments that use RNA interference, a technology that turns off specific genes to stop disease.

For a long-term owner, these conferences are important because they provide the clinical proof needed to convince doctors to switch patients to Alnylam's drugs. Success in the heart disease market is the primary driver of the company's future growth, so any data that reinforces its edge over older treatments is a key development to watch.

Source: Business Wire

Bernstein set a price target of $376 for the stock, which is significantly higher than the current price of about $239. This target is also above the average analyst target of $355. While a price target is just one firm's estimate of what the stock could be worth, it reflects confidence in the company's transition from a niche biotech firm into a profitable business. The gap between the current price and these targets suggests analysts see much more value in the company's heart disease treatments than the market is currently pricing in.

Source: Bernstein

Wells Fargo maintained its Equal Weight rating, which is a neutral stance that suggests the stock will likely perform in line with the broader market. The firm lowered its price target from $316 to $256, bringing it closer to the current trading price. While this is a notable drop in the target price, the average analyst target remains much higher at about $362. This suggests that while Wells Fargo is more cautious, many other analysts still see significant room for the stock to rise from its current level of about $243.

Source: Wells Fargo

Metrics we are tracking